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Abstract
Objective
Mucosal-associated invariant T (MAIT) cells comprise a subpopulation of T cells that can be
activated by bacterial products and cytokines to produce IFN-γ. Since little is known on
MAIT cells during HCV infection, we compared their phenotype and function in comparison
to HIV and HCV/HIV co-infected patients, and determined the effect of IFN-α-based and
direct-acting antiviral therapy on MAIT cells of HCV patients.
Methods
Blood samples from patients with chronic HCV (CHCV), virologically suppressed HIV, acute
HCV/HIV co-infection (AHCV/HIV) and healthy individuals were examined by flowcytometry
for phenotype and function of MAIT and NK cells.
Results and Conclusions
Compared to healthy individuals, the frequency of CD161+Vα7.2+ MAIT cells was signifi-
cantly decreased in patients with CHCV, HIV and AHCV/HIV co-infection. CD38 expression
on MAIT cells was increased in AHCV/HIV patients. MAIT cells were responsive to IFN-α in
vitro as evidenced by enhanced frequencies of IFN-γ producing cells. IFN-α-based therapy
for CHCV decreased the frequency of IFN-γ+ MAIT cells, which was still observed 24 weeks
after successful therapy. Importantly, even after successful IFN-α-based as well as IFN-α-
free therapy for CHCV, decreased frequencies of MAIT cells persisted. We show that the
frequencies of MAIT cells are reduced in blood of patients with CHCV, HIV and in AHCV/
HIV co-infection compared to healthy individuals. Successful therapy for CHCV did not nor-
malize MAIT cell frequencies at 24 weeks follow up. The impact of HIV and HCV infection
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on the numbers and function of MAIT cells warrant further studies on the impact of viral
infections and the antimicrobial function of MAIT cells.
Introduction
Following infection with hepatitis C virus (HCV), hepatocytes are triggered to produce type I
and III interferons (IFN), which induce the expression of hundreds of IFN stimulating genes
(ISG) with anti-viral activity [1–3]. However, despite the induction of ISG, viral titers increase
during acute HCV infection, and in the majority of infected individuals the virus is able to
establish a chronic infection of the liver, which indicates that the immune response is ineffec-
tive [4, 5]. Besides the induction of ISG, IFN also activates natural killer (NK) cells, T cells and
dendritic cells (DCs), and are therefore important immunomodulators [2, 6–9]. Similar as in
HCV, type I IFN are produced in large amounts after infection with human immunodeficiency
virus (HIV), causing induction of antiviral responses that target every step of the HIV life cycle
[9].
In recent years, our understanding of Mucosal-Associated Invariant T (MAIT) cells in
chronic HIV infection has increased substantially. Most MAIT cells are CD8+ or double nega-
tive for CD4 and CD8, and characterized by the expression of CD161 and the invariant T cell
receptor (TCR) Vα7.2 that recognizes vitamin metabolites presented by MR1, a MHC class I
related protein, on the surface of antigen-presenting cells [10, 11]. MAIT cells are also activated
by IL-12 and IL-18 in an MR1-independent manner [12]. MAIT cells are abundant in human
blood (1–10% of CD8+ T cells) and are known for their antimicrobial activity to bacteria and
yeast in the gut and lungs [13, 14] via release of cytokines and cytotoxic enzymes [10]. Interest-
ingly, MAIT cells are reduced in peripheral blood and lymph nodes of patients with chronic
HIV infection, and their cytokine production and cytolytic functions are severely affected
which has been suggested to be the result of exhaustion. Importantly, the loss and dysfunction
of MAIT cells are not recovered after successful combination antiretroviral therapy (cART)
therapy [15–22]. It has been suggested that the functional impairment and numerical decline
of MAIT cells contributes to the high incidence of bacterial infections observed in HIV patients
[18]. At the moment it is unclear what causes the depletion of MAIT cells in HIV infection.
Similar findings were reported recently in patients chronically infected with HCV where the
MAIT cell numbers in blood were severely reduced during persistent infection [23]. Also in
chronic HCV, successful HCV clearance by IFN-free therapy does not result in normalization
of MAIT cell numbers.
Because little information is available on the role of MAIT cells in HCV infection, we exam-
ine in this study the impact of HCV infection on MAIT cells. In addition, we investigate the
consequence of IFN-α exposure on NK cells and MAIT cells during IFN-α based therapy for
CHCV and acute-HCV/HIV co-infection.
Materials and Methods
Patients and healthy subjects
Heparinized blood was collected from 33 patients with chronic HCV (CHCV) infection, 9
acute HCV patients with cART-suppressed HIV (AHCV/HIV), 10 patients with cART-sup-
pressed HIV mono-infection and 12 healthy subjects. The patient characteristics are listed in
table 1. 33 CHCV patients were treated in 4 different historical treatment regimens, and blood
was collected at multiple time-points. In cohort 1, 11 patients were treated with pegylated-IFN-
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alpha-2a (PegIFN-α) and ribavirin for 24 or 48 weeks, according to HCV genotype
(NCT00422838, [24]). Patients in cohort 2 (n = 11) were treated with telaprevir, PegIFN-α and
ribavirin for 24 or 48 weeks, according to their fibrosis level and previous treatment response
to PegIFN-α and ribavirin. Consistent with international guidelines [25], patients were treated
with telaprevir, PegIFN-α and ribavirin for the first 12 weeks, and continued treatment consist-
ing of PegIFN-α and ribavirin only (NCT01641094). In this treatment cohort, naïve patients,
patients with a partial response (>2log drop in viral load) to previous IFN-based therapy, and
patients without cirrhosis were treated for 24 weeks when HCV RNA was undetectable (<15
IU/l) at week 4 and 12 during therapy. In cohort 3, 5 patients were treated with daily daclatasvir
and twice daily asunaprevir for 24 weeks (NCT02282709, [26]). In cohort 4, 6 patients were
treated with sofosbuvir and daclatasvir with or without ribavirin for 12 or 24 weeks according
to the international guidelines (AASLD/IDSA Recommendations for testing, managing, and
treating hepatitis C 2015 (hcvguidelines.org) and EASL: recommendations on treatment of
hepatitis C 2015). The selection of the treatment regimen was solely made by the treating phy-
sician. For patients with CHCV, blood was collected at baseline, week 4, week 12 during ther-
apy and 24 weeks after end of therapy in all 4 cohorts. Patients with acute HCV and cART-
suppressed HIV were treated in cohort 5 (n = 9). Patients were treated within 26 weeks after
HCV infection with 12-weeks boceprevir, PegIFN-α and ribavirin (NCT01912495). Blood was
collected at baseline and at week 4 during therapy. Patients with cART-suppressed HIV mono-
infection (n = 10) and 22 healthy subjects (67% male, average age: 54 (range 42–70)) were
included as controls. The institutional ethical review board of the Erasmus Medical Center
approved the protocols, and written informed consent was obtained from all individuals.
Analysis of cell surface molecule expression by flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated from venous blood by (Ficoll-
Paque™ plus, Amersham) and frozen at -150°C. PBMC were thawed and washed with RPMI
1640 (Lonza) with 10% FCS (Lonza). For flow cytometry, 500,000 PBMC were used for each
Table 1. Patient characteristics.
All
CHCV
CHCV CHCV CHCV CHCV AHCV/HIV HIV
cohort 1 cohort 2 cohort 3 cohort 4 cohort 5
Treatment
strategy
PegIFN/riba PegIFN/riba
telaprevir
Asunaprevir
daclatasvir
Sofosbuvir
daclatasvir
PegIFN/riba
boceprevir cART
cART
Number 33 11 11 5 6 9 10
Gender (% male) 73 82 80 67 100 100
Age (mean, yrs) 45 (27–60) 50 (25–61) 52 (43–66) 59 (36–70) 40 (23–58) 49 (27–65)
HCV RNA(mean,
IU/ml)
4.6x106 (3.7x102-
2.7x107)
2.90x106 (3.5x104-
8.2x106)
1.2 x106 (1.6x105-
2.3x106)
2.7 x106 (8.3x104-
5.3x106)
0.3 x106 (2.0x102-
1.9x106)
ALT (mean, U/l) 79 (34–164) 70 (29–140) 188 (94–269) 126 (24–196) 324 (33–1070)
Fibrosis (%) 0-1/2/
3/4/n.d.
30/50/20/0/0 27/18/36/18/0 80/0/0/20/0 0/0/33/67
SVR (%) 82 82 100 100 100
HCV genotype (%)
1/2/3/4
36/18/46/0 100/0/0/0 100/0/0/0 83/17/0/0 100/0/0/0
HIV Load <20 geq/
ml (%)
100 80
CD4 (mean, x109/
ml)
0.87 (0.64–1.37) 0.67 (0.47–
0.96)
doi:10.1371/journal.pone.0159243.t001
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staining. Cells were stained with anti-CD38-PerCp-eFluor710 (HB7), anti-CD3-PE-Cy7
(UCHT1), anti-CD161-Pacific Blue (HP-3G10, all eBiosciences), anti-CD4-APC-H7 (SK3, BD
Biosciences), anti-TCR Vα7.2-PE (3C10, Biolegend), anti-CD56-APC (N901, Beckman) and
live/dead marker (Aqua, Life technologies) for 20 minutes at 4°C in the dark. Positivity for
CD38 was determined by setting the gates using internal negative cells. Cells were washed and
marker expression was detected by flow cytometry (Canto-II, BD). MAIT cells were defined as
CD3+CD161+Vα7.2+ cells within the lymphocyte gate and NK cells were defined as
CD3-CD56+ cells within the lymphocyte gate. Data was analyzed using FlowJo version 10.1
(Tree Star Inc).
Analysis of intracellular cytokines by flow cytometry
The percentage of cells producing IFN-γ was measured by flowcytometry using various stimuli.
For each condition, 500,000 cells were stimulated in a 24 wells plate with IL-12 (0.25 ng/ml,
Miltenyi), IL-18 (50 ng/ml, MBL) and IFN-α (2500 IU/ml, Intron-A, Merck). For all condi-
tions, cells were stimulated for 16 hours at 37°C at 5% CO2. Brefeldin A (10 μg/ml, Sigma) was
added and the cells were incubated for another 3 hours. Cells were stained with anti-CD3-
PerCp-Cy5.5 (UCHT1), anti-CD4-APC-H7 (SK3, both BD biosciences), anti-CD69-PE-Cy7
(TPI.55.3), anti-CD161-PB (HP-3G10, both eBiosciences), anti-TCR Vα7.2-PE (3C10, Biole-
gend), anti-CD56-APC (N901, Beckman) and Live/ dead marker (Aqua, Life technologies).
Cells were fixed, permeabilized and stained with anti-IFN-γ-FITC (25723.11, BD Biosciences).
Cytokine-producing cells were detected by flow cytometry (Canto-II, BD). Quadrants were set
on low or absent expression on lineage negative cells. Data was analyzed using FlowJo version
10.1 (Tree Star Inc).
Statistics
Statistical comparison was tested using the Kruskal-Wallis and Mann-Whitney test for
unpaired non-parametric analyses and the Paired student t-test for paired observations. A p
value 0.05 was considered significant. All data was analysed using GraphPad Prism (Graph-
Pad Software).
Results
MAIT cells are decreased in patients with chronic HCV, HIV and AHCV/
HIV co-infection compared to healthy controls
We investigated whether MAIT cells are affected during chronic viral infections and compared
them to NK cells. For this purpose, the frequencies of CD3+CD161+Vα7.2+ MAIT cells and
CD3-CD56+ NK cells were determined in peripheral blood of patients with CHCV, HIV,
AHCV/HIV and healthy individuals by flow cytometry (Fig 1A and 1B). A significant decrease
was observed in the frequencies of MAIT cells in CHCV, HIV and AHCV/HIV patients as
compared to healthy controls (p = 0.004, p = 0.04 and p = 0.01, respectively, Fig 1B). No differ-
ences were observed in frequencies of NK cells in patients with AHCV/HIV co-infection com-
pared to healthy controls [27–30], whereas NK cells in CHCV and HIV mono-infected
patients were decreased compared to healthy controls (p = 0.009 and p = 0.003, respectively)
(Fig 1B). Next, we determined the expression of the activation marker CD38 on MAIT cells
and observed that patients with AHCV/HIV co-infection had increased frequencies of acti-
vated MAIT cells in peripheral blood compared to HIV, CHCV and healthy individuals
(p = 0.01, p<0.001, p = 0.002 respectively, Fig 1B). No association between the frequency of
MAIT cells and ALT levels (r-value: -0.185, p = 0.42) or viral load (r-value: 0.019, p = 0.93) was
Circulating MAIT Cells in HIV and HCV Infections
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Fig 1. Frequencies of MAIT cells are decreased in patients with CHCV, HIV and AHCV/HIV co-infections compared to healthy
individuals. (A) Representative dot plots and gating strategy of CD3+CD161+ Vα7.2+ MAIT cells and CD3-CD56+ NK cells. (B) The
percentage of MAIT cells within the CD3+ T cell population, NK cells within the lymphocyte population, and CD38+MAIT cells within the total
MAIT cell population of healthy individuals (n = 22 for frequencies of MAIT and NK cells; n = 12 for frequencies of CD38+ MAIT cells), chronic
HCV (CHCV) patients (n = 33), cART-suppressed HIV (HIV) patients (n = 10) and patients with acute HCV/HIV co-infection (AHCV/HIV)
(n = 9). (C) Frequency of MAIT cells within the CD3+ T cell population in CHCV patients do not correlate with ALT, HCV RNA or fibrosis score
levels. No association between the frequency of MAIT cells and ALT levels (r-value: -0.185, p = 0.42) or viral load (r-value: 0.019, p = 0.93)
was observed. Statistical comparison was tested using Mann-Whitney test for unpaired analyses. Spearman’s correlation test was used for
the first two panels of Fig 1C.
doi:10.1371/journal.pone.0159243.g001
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observed (Fig 1C). Also, stratification of patients with CHCV of their fibrosis stage showed
similar frequencies of MAIT cells (Fig 1C).
Frequency of IL12/IL-18 induced IFN-y producing MAIT cells does not
differ between patients with CHCV, HIV, AHCV/HIV co-infection or
healthy individuals
Next, we determined the ability of MAIT cells from the various patient groups to respond to
IL-12/18 as well as to IFN-α/IL-18 and evaluated CD69 surface expression and production of
IFN-γ. A representative dot plot and gating strategy after stimulation of CHCV peripheral
blood with IL-12/18 is shown in Fig 2A. As shown in Fig 2B, CD69 expression on both MAIT
cells and NK cells was upregulated upon stimulation with IL-12/18 and IFN-α/IL-18, as com-
pared to medium control conditions. The frequency of IFN-γ producing MAIT cells was signif-
icantly increased upon stimulation with IL-12/18. Importantly, IFN-α was also found to be a
potent activator of MAIT cells (Fig 2B). Next, we determined the function of MAIT cells in dif-
ferent viral infections and observed that MAIT cells are equally capable to become activated
and produce IFN-γ upon stimulation with IL-12/18 and IFN-α/IL-18 in CHCV, HIV, AHCV/
HIV co-infection and healthy individuals (Fig 2C).
IFN-based therapy for chronic HCV reduces the frequency of IFN-γ
producing MAIT cells upon IL-12/IL-18 stimulation
Fig 2B shows that IFN-α is a potent stimulator of MAIT cells in vitro. Since IFN-α has potent
antiviral activity against HCV, we determined whether IFN-α-based therapy for CHCV acti-
vates MAIT cells and affects MAIT cell frequencies in CHCV and AHCV/HIV co-infection.
Twenty-two CHCV patients were treated with IFN-based therapy with (n = 11) or without
(n = 11) telaprevir. All patients were HCV RNA negative at week 12 during therapy. We
observed that IFN-α-based therapy did not alter MAIT cell frequencies, but did increase CD38
expression on MAIT cells (p<0.001, Fig 3A, upper panels). No difference was observed
between treatment with or without addition of telaprevir (S1 Fig). The NK cell frequency was
reduced early during IFN-based therapy (p<0.001), but this was not sustained at week 12 (Fig
3A, upper panels). Recently, IFN-free therapy became available for clinical use and has substi-
tuted IFN-α-based therapy because of higher SVR rates and reduced side-effects. Eleven
CHCV patients were treated with an IFN-free regimen and we determined if the observed
effects on MAIT cells were due to a direct effect of IFN-α or to viral load decline. In all patients,
HCV RNA titers were undetectable after 4 weeks of treatment; however, no effect was observed
on MAIT cell frequency or activation (Fig 3A, middle row). In addition, no effect was observed
on NK cell frequencies (Fig 3A, middle panels). These data suggest that the increased frequen-
cies of CD38-expressing MAIT cells in CHCV patients is the consequence of exposure to IFN-
α, rather than of viral load decline.
Patients with AHCV/HIV co-infection were treated with a combination of boceprevir,
PegIFN-α and ribavirin; all patients were HCV RNA negative at week 4 during therapy. IFN-
α-based therapy did not alter MAIT cell or NK cell frequencies in this patient population (Fig
3A, lower panels). The enhanced expression of CD38 on MAIT cells of patients with AHCV/
HIV co-infection (Fig 1) was not further increased during therapy (Fig 3A, lower panels).
To investigate whether MAIT cell function was altered during therapy for HCV, cells were
stimulated with IL-12/18. Surprisingly, although IFN-α-based therapy for CHCV caused
increased expression of activation marker CD38 on MAIT cells as shown in Fig 3A, a decrease
in the frequency of IFN-y producing MAIT cells was observed upon stimulation with IL-12/18
during therapy compared to medium (p = 0.02 at week 4, p = 0.03 at weeks 12; Fig 3B, upper
Circulating MAIT Cells in HIV and HCV Infections
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Fig 2. MAIT cells function does not differ between patients with chronic HCV, HIV and AHCV/HIV co-
infection. (A) Representative dot plots of CD69 expression and IFN-γ production by MAIT and NK cells in
CHCV after stimulation with IL-12/IL-18. (B) Frequency of CD69 expression and IFN-γ producing MAIT cells
and NK cells in CHCV patients after 19 hours stimulation with medium, IL-12/IL-18 and IFN-α/IL-18. (C)
Frequency of IFN-γ producing MAIT cells after various stimuli between healthy individuals, patients with
CHCV, HIV and AHCV/HIV co-infection. Statistical comparison was tested using paired T test (2B) and
Mann-Whitney test (2C).
doi:10.1371/journal.pone.0159243.g002
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Fig 3. IFN-based therapy for chronic HCV increases expression of CD38 on MAIT cell but reduces MAIT cell
function. (A) Frequency of MAIT, CD38+MAIT cells and NK cells during IFN-based therapy for CHCV (cohorts 1 and
2, n = 22), IFN-free therapy for CHCV (cohort 3 and 4, n = 11) and IFN-based therapy for AHCV/HIV co-infection
(cohort 5, n = 9). At week 12 during therapy for CHCV and at week 4 during therapy for AHCV/HIV, all patients were
HCV RNA negative. (B) Frequency of IFN-γ producing MAIT cells after stimulation with IL-12/18, and medium during
Circulating MAIT Cells in HIV and HCV Infections
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panels). Neither in CHCV patients treated with IFN-free therapy, nor in patients with AHCV/
HIV co-infection, therapy altered the frequencies of IFN-γ producing MAIT cells (Fig 3B, mid-
dle and lower panels).
Successful therapy for chronic HCV does not restore MAIT cell
frequency 24 weeks after therapy
Besides evaluation of the effect of therapy on phenotype and function of MAIT cells, it is highly
relevant to determine the effect of viral clearance. Blood was collected 24 weeks after end of
therapy. No samples from patients with AHCV/HIV co-infection were available after therapy.
Fig 4 shows that 24 weeks after cessation of IFN-based therapy as well as IFN-free therapy, the
MAIT cell frequencies were not restored in CHCV patients and remained low (Fig 4, upper
panels). The increased expression of CD38 on MAIT cells during IFN-based therapy for
CHCV (Fig 3A) was not maintained 24 weeks after therapy and returned to pre-treatment lev-
els (Fig 4). Interestingly, the suppressive effect of IFN-based therapy on IFN-y producing
IFN-based and IFN-free therapy for CHCV infection (baseline, 4wk, 12wk), and during IFN-based therapy for AHCV/
HIV (baseline, 4wk). The baseline frequencies of CD38+ MAIT cells and IFN-γ+ MAIT cells of the patient groups
receiving IFN-based and IFN-free therapy were similar (MannWhitney test). All other statistical comparisons were
tested usingWilcoxon matched pairs T test.
doi:10.1371/journal.pone.0159243.g003
Fig 4. Frequency of MAIT cells in peripheral blood of chronic HCV patients does not recover after
successful therapy. Frequencies of MAIT, CD38+MAIT and IFN-γ+ MAIT cells before and 24 weeks after
successful IFN-based (left, n = 22) and IFN-free (right, n = 9) therapy for CHCV. Frequencies of IFN-γ+ MAIT
cells were measured after 19 hours stimulation with IL-12/18. Statistical comparison was tested using
Wilcoxon matched pairs T test.
doi:10.1371/journal.pone.0159243.g004
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MAIT cells as shown in Fig 3, was still observed 24 weeks after cessation of therapy upon IL-
12/IL-18 stimulation (p = 0.002, Fig 4). Therefore, it appears that IFN-based therapy for
CHCV affects IFN-y producing MAIT cells at least up to 24 weeks after therapy. No differences
in frequencies of MAIT cells, CD38+ MAIT cells or IFN-γ producing MAIT cells were observed
before and 24 weeks after IFN-free therapy for CHCV (Fig 4, right panels).
Discussion
In this study we performed a detailed analysis on MAIT cells in CHCV, HIV and AHCV/HIV
infections. We observed that the frequency of MAIT cells is decreased in all three groups of
infected patients compared to healthy individuals, and that no normalization was observed fol-
lowing successful anti-HCV therapy at a follow-up period of 24 weeks. Moreover, the fre-
quency of IFN-y producing MAIT cells upon IL-12/IL-18 stimulation was reduced in blood
from HCV patients receiving IFN-α-based therapy, but not in blood from patients receiving
IFN-free therapy.
Our findings on reduced MAIT cell frequencies in HIV and HCV are in line with others
[15–18, 31]. We confirmed the recent study by Hengst et al. [23] by showing reduced frequen-
cies of CD161+Vα7.2+MAIT cells in peripheral blood of CHCV patients, long after viral clear-
ance. From our studies, we cannot conclude whether the reduced frequencies of MAIT cells are
due to depletion of cells via apoptosis, migration of MAIT cells from blood to peripheral organs
or skin, or due to down-regulation of characteristic markers, such as CD161. However, others
have demonstrated that it is unlikely that CD161 down-regulation is responsible for the
observed MAIT cell numbers in HIV infection [19]. In addition, it has been shown that MAIT
cells are systemically depleted in simian immunodeficiency virus infected rhesus macaques, a
model often used to investigate HIV [32]. This suggests that migration of MAIT cells to periph-
eral organs in HIV is less likely. More research is needed to clarify the cause of the depletion in
HIV and HCV. Importantly, virus eradication by IFN-based therapy as well as by IFN-free
therapy did not lead to normalization of the reduced MAIT cell frequencies at 24 weeks after
cessation of therapy. These findings are similar to the observations by Hengst et al. who showed
nonreversible MAIT dysfunction 48 weeks after end of treatment with sofosbuvir and ribavirin
[23]. The long-term complications of low MAIT cell frequencies may be an increased suscepti-
bility of bacterial infections after viral clearance. These observations are reminiscent of the
findings reported in HIV where long-term suppression of viral replication by cART does not
result in normalization of MAIT numbers in blood [15, 17, 18]. It is well-known that the
immune system in cART-controlled HIV patients remains at a higher activation status as com-
pared to control healthy individuals, but it is unknown whether the enhanced immune activa-
tion mediates MAIT cell depletion. Besides a lower frequency of MAIT cells, we also observed
a lower frequency of NK cells in HIV patients compared to CHCV and healthy individuals
(p = 0.02 and p = 0.02). Decreased NK cell frequencies and function in HIV patients has been
described before to be associated with a more rapid progression to AIDS in untreated patients
[33].
Besides their numbers, the function of MAIT cells is also an important determinant of their
contribution to the overall response to HIV or HCV. As shown in this manuscript and reported
by others, MAIT cells are highly responsive to IL-12/IL-18 [12, 16]. We now show that MAIT
cells are also responsive to the combination of IFN-α and IL-18, leading to the production of
IFN-γ. The ability of MAIT cells to respond to IFN-α is shared with NK cells.
The function of MAIT cells, as reflected by the frequency of IFN-y producing MAIT cells
upon IL-12/IL-18 stimulation was similar in patients with CHCV, HIV or AHCV/HIV as com-
pared to healthy individuals. Recently, dysfunctional MAIT cells from chronic HCV patients
Circulating MAIT Cells in HIV and HCV Infections
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with respect to their ability to produce IFN-γ were observed upon MR1-dependent antigen
stimulation, but -similar to our findings- not upon IL-12/IL-18 stimulation [23]. However,
since MAIT cells are decreased in these patients groups, the total amount of IFN-y by these
MAIT cells is likely to be decreased. Also the activation state of MAIT cells from CHCV and
HIV patients were not affected. In contrast, MAIT cells from AHCV/HIV patients exhibited
higher frequencies of CD38-expressing MAIT cells, which may be the result of exposure to
pro-inflammatory serum cytokines that are known to be present at relatively high levels during
acute HCV infection [34].
Viral load reduction by DAA-therapy in CHCV patients did not affect MAIT cell activation
or IFN-γ+ frequencies, whereas IFN-based therapy strongly affected both parameters. We
observed that IFN-based therapy enhanced the expression of the activation marker CD38 on
MAIT cells, but decreased the frequencies of IFN-y producing MAIT cells. Since the activation
state of MAIT cells during IFN-based therapy is augmented, it is unlikely that the effect on
IFN-y production is the result of an overall inhibitory effect on the MAIT cells, but it may be
the consequence of functional paralysis due to prolonged exposure to IFN-α. Although highly
speculative, this may also explain the opposing effects of IFN-α on the frequencies of IFN-y
producing MAIT cells upon short-term exposure in vitro and long-term exposure in vivo. The
observation that IFN-based therapy, but not DAA-therapy, suppresses the functionality of
MAIT cells, may indicate that a disadvantage of IFN-based-therapy over DAA therapy is that it
affects the anti-microbial function of MAIT cells and that the reduced functionality of MAIT
cells may render individuals more susceptible to pathogens.
In conclusion, we show that MAIT cells are decreased in patients with chronic HCV, HIV
and AHCV/HIV co-infection compared to healthy controls. We show that IFN-αmodulates
MAIT cells in vitro, and in vivo during IFN-based therapy for HCV but importantly, a sus-
tained viral response for HCV does not rescue MAIT cell frequency.
Supporting Information
S1 Fig. No clear differences are observed between CHCV patients treated with IFN/based
therapy with or without telaprevir. Patients with CHCV were treated with peginterferon and
ribavirin alone (n = 9) or in combination with telaprevir for 12 weeks (n = 11). All patients
were responsive to either treatment and were HCV RNA negative at week 12 of therapy (<15
U/ml). Frequencies of MAIT, CD38+MAIT and NK cells before and 12 weeks during therapy
are shown.
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